Industry Press Releases

SpeeDx Distribution Network expands its presence to the Middle East

Tuesday, Mar 19, 2019

SpeeDx Pty. Ltd. announced the integration of new Al Zahrawi Medical Supplies LLC partners for the distribution of Resistance Plus ® and Plex PCR ® tests in the United Arab Emirates, Saudi Arabia, Oman, Bahrain and Qatar.

"Al Zahrawi Medical is the leading provider of medicine and diagnostics in the region and will be the perfect partner to expand our business to the Gulf Cooperation Council (GCC)," said Colin Denver, chief executive officer of SpeeDx. "Our products address the global issues of antibiotic resistance and reproductive health. With this agreement, we are pleased that more laboratories can now access our ResistancePlus tests to detect Mycoplasma genitalium and gonorrhea, leading to resistance-oriented therapy to patients around the world. "

SpeeDx's Resistance Plus tests provide valuable information, combining infection detection with genetic markers linked to antibiotic resistance, allowing physicians to make informed treatment decisions. Resistance-guided therapy has been heralded as a breakthrough in the control of bacterial infections, providing physicians with information about the susceptibility to infection or the status of resistance to common first-line antibiotics, improving cure rates and reducing overall costs of Cheers. 1, 2

The Resistance Plus GC * combines the detection of Neisseria gonorrhoeae with markers for susceptibility to ciprofloxacin; the Resistance Plus MG * simultaneously detects Mycoplasma genitalium and genetic markers for resistance to azithromycin. SpeeDx also plans to launch a new Resistance Plus MG test for resistance markers linked to second-line antibiotic treatment failures, as well as a Resistance Plus MP test for macrolide resistance markers and Mycoplasma pneumoniae . The SpeeDx portfolio also includes thePlex PCR VHS, a multiplex test for herpes simplex virus (1 and 2), varicella-zoster and Treponema pallidum (syphilis), and the Plex PCR HSV-1, 2 & VZV, multiplex molecular panel for herpes virus.

* Not available in the United States.

References
1. O'Neill J. The Review on Antimicrobial Resistance. May 2016: 35
2. Read TRH et al CID June 5, 2018 doi.org/10.1093/cid/ciy477.

About SpeeDx

Founded in 2009, SpeeDx is a privately held company headquartered in Australia, with offices in London and the USA, as well as distributors throughout Europe. SpeeDx specializes in molecular diagnostic solutions that go beyond simple detection, offering comprehensive information for better patient management. The innovative real-time polymerase chain reaction (qPCR) technology has boosted market-leading multiplex detection and priming strategies. SpeeDx has a portfolio of CE-IVD kits for the detection of infectious disease pathogens, sexually transmitted infections (STIs) and antimicrobial resistance markers. Currently,Resistance Plus enable resistance-oriented therapy, improving patient outcomes, and enabling practitioners to make informed clinical decisions.
For more information about SpeeDx, visit http://plexpcr.com.

The text in the original language of this ad is the official authorized version. The translations are provided only as a facility and must refer to the text in the original language, which is the only version of the text that has legal effect.

Contacts
Madeline O'Donoghue
global marketing manager
madelineo@speedx.com.au
+61 2 9209 4170


Source: businesswire.com

Other Press Releases